Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate

British Journal of Anaesthesia

Volumn 113, Issue 4, 2014, Pages 585-595

  Collins, P W ^a   Solomon, C ^b,c   Sutor, K ^d   Crispin, D ^d   Hochleitner, G ^e   Rizoli, S ^f   Schochl H ^g,h   Schreiber, M ⁱ   Ranucci, M ^j  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CSL BEHRING GMBH   (Germany)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d Meridian HealthComms   (United Kingdom)

^e CSL Behring   (Austria)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g AUVA Trauma Hospital   (Austria)

^h LUDWIG BOLTZMANN INSTITUTE FOR EXPERIMENTAL AND CLINICAL TRAUMATOLOGY   (Austria)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j IRCCS POLICLINICO SAN DONATO   (Italy)

more..

Author keywords

Computer simulation; Cryoprecipitate; Drug dosage calculations; Fibrinogen; Plasma

Indexed keywords

FIBRINOGEN; FIBRINOGEN CONCENTRATE; HEMOSTATIC AGENT;

ARTICLE; COMPUTER SIMULATION; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; FIBRINOGEN BLOOD LEVEL; HUMAN; MATHEMATICAL MODEL; PLASMA; PRIORITY JOURNAL; SUPPLEMENTATION; THEORETICAL MODEL; THERAPEUTIC PLASMA; BLOOD VOLUME; BODY HEIGHT; CHEMISTRY; DOSE CALCULATION; DOSE RESPONSE; ERYTHROCYTE; HEMATOCRIT; PHYSIOLOGY;

COMPUTER SIMULATION; CRYOPRECIPITATE; DRUG DOSAGE CALCULATIONS; FIBRINOGEN; PLASMA;

BLOOD VOLUME; BODY HEIGHT; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FIBRINOGEN; HEMATOCRIT; HEMOSTATICS; HUMANS; MODELS, THEORETICAL; PLASMA;

EID: 84908621878     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu086     Document Type: Article

References (40)

1. Hiippala ST, Myllyla GJ,Vahtera EM.Hemostatic factorsand replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-5
2. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5: 266-73
3. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10: 1342-51
4. Ucar HI, Oc M, Tok M, et al. Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery. Heart Surg Forum 2007; 10: E392-6
5. Gorlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery:aretrospective, single-center cohort study. Anesthesiology 2011; 115: 1179-91
6. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76
7. Kozek-Langenecker S, Sorensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15: R239
8. Warmuth M, Mad P, Wild C. Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults. Acta Anaesthesiol Scand 2012; 56: 539-48
9. Yang L, Stanworth S, Baglin T. Cryoprecipitate: an outmoded treatment? Transfus Med 2012; 22: 315-20
10. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382
11. Levy JH,Welsby I, Goodnough LT. Fibrinogen as atherapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014; 54: 1389-405
12. UKBloodTransfusion&TissueTransplantation Services.Transfusion Handbook. Available from http://www.transfusionguidelines.org. uk/index.aspx?Publication=HTM (accessed January 2013)
13. Lee SH, Lee SM, Kim CS, et al. Fibrinogen recovery and changes in fibrin-based clot firmness after cryoprecipitate administration in patients undergoing aortic surgery involving deep hypothermic circulatory arrest. Transfusion 2014; 54: 1379-87
14. Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104: 555-62
15. American Association of Blood Banks (AABB); American Red Cross; America's Blood Centers; and the Armed Services Blood Program. Circular of information for the use of human blood and blood components. 2009. Available from http://www.aabb.org/resources/bct/Documents/coi0809r.pdf (accessed July 2013)
16. Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev 2003; 17: 223-31
17. Arya RC, Wander G, Gupta P. Blood component therapy: which, when and how much. J Anaesthesiol Clin Pharmacol 2011; 27: 278-84
18. Canadian Blood Services. Clinical guide to transfusion. Available fromhttp://www.transfusionmedicine.ca/sites/transfusionmedicine/files/CBS-CGT-BM.pdf (accessed January 2013)
19. Elzik ME, Dirschl DR, Dahners LE. Correlation of transfusion volume to change in hematocrit. Am J Hematol 2006; 81: 145-6
20. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of red blood cells. Blood Transfus 2009; 7: 49-64
21. Vermeulen Windsant IC, de Wit NC, Sertorio JT, et al. Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study. Crit Care 2012; 16: R95
22. GermanMedical Association. Cross-sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th revised Edn, 2009. Available from https://www.iakh.de/tl-files/iakh/public/richtlinien/Querschnittsleitlinie-4.-Auflage-englisch-05.01 .2011%20copy.pdf (accessed July 2013)
23. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care: Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-17
24. Nijboer JM, van der Horst IC, Hendriks HG, ten Duis HJ, Nijsten MW. Myth or reality: hematocrit and hemoglobin differ in trauma. J Trauma 2007; 62: 1310-2
25. Gorlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013; 27: S20-34
26. Cunningham FG. Laboratory values in normal pregnancy. Available from http://onlinelibrary.wiley.com/doi/10.1002/9781444323870 .app2/pdf (accessed May 2013)
27. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118: 40-50
28. Schochl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14: R55
29. Fries D, Innerhofer P, Reif C, et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesth Analg 2006; 102: 347-51
30. American Society of Anesthesiologists Committee on Blood Management. Massive transfusion protocol (MTP) for hemorrhagic shock. Available from: http://www.asahq.org/For-Members/Standards-Guidelines-And-Statements.aspx (accessed July 2013)
31. Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013; 148: 127-36
32. Johansson PI, Stensballe J. Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang 2009; 96: 111-8
33. Dempfle CE, Kalsch T, Elmas E, et al. Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots. Blood Coagul Fibrinolysis 2008; 19: 765-70
34. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009; 102: 793-9
35. Weiss G, Lison S, Glaser M, et al. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register. Blood Coagul Fibrinolysis 2011; 22: 727-34
36. Stinger HK, Spinella PC,Perkins JG, et al. Theratio of fibrinogento red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64: S79-85
37. Hirshberg A, Dugas M, Banez EI, Scott BG,WallMJ Jr.,Mattox KL. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003; 54: 454-63
38. Ho AM, Dion PW, Cheng CA, et al. A mathematical model for fresh frozen plasma transfusion strategies during major trauma resuscitation with ongoing hemorrhage. Can J Surg 2005; 48: 470-8
39. Bhananker SM, Ramaiah R. Trends in trauma transfusion. Int J Crit Illn Inj Sci 2011; 1: 51-6
40. Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009; 66: 1616-24